| Literature DB >> 24228062 |
Maizura Mohd Zainudin1, Zaiton Zakaria, Nor Anita Megat Mohd Nordin, Faizah Othman.
Abstract
The prevalence of diabetes mellitus has reached epidemic proportion in Malaysia and worldwide. Scientific studies have shown that herbal plant Piper sarmentosum exhibits an antidiabetic property. Despite the extensive usage and studies of this herb as alternative medicine, there is paucity of the literature on the safety information of this plant. Thus, the present study aimed to observe the subacute toxic effects of Piper sarmentosum aqueous extract (PSAE) on the haematological profile, liver, and kidney in rats. The extract was administered by oral gavage to 6 male and female Sprague Dawley rats in daily dose of 50 mg/kg, 300 mg/kg, and 2000 mg/kg for 28 consecutive days. The control group received normal saline. General behavior of the rats, adverse effects, and mortality were observed for 28 days. The haematological and biochemical parameters were determined at baseline and after the treatment. PSAE did not show abnormality on the body weight and gross observation of internal organs. The haematological, biochemical and histopathological profiles showed minimal changes and variation within normal clinical range except for significant increase in serum potassium level that suggests the need of regular monitoring. Nevertheless, these findings suggested that PSAE up to 2000 mg/kg/day did not show subacute toxicity in Sprague Dawley rats.Entities:
Year: 2013 PMID: 24228062 PMCID: PMC3817794 DOI: 10.1155/2013/705950
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Showing changes in the body weight of rats in various groups throughout the study period. Data were expressed as mean ± SEM. *P value <0.05 is significant compared to control group; # P value <0.05 is significant compared to baseline value; P value <0.05 is significant compared to other groups.
Table showing changes in the food and water consumption of rats throughout the experimental period.
| Control |
| |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Male | ||||
| Water consumption (mL) | ||||
| Control | 31.0 ± 1.2 | 36.3 ± 0.8 | 40.4 ± 1.6 | 44.6 ± 2.4 |
| PSAE 50 mg/kg | 32.4 ± 3.5 | 38.1 ± 4.4 | 36.4 ± 4.1 | 38.8 ± 4.0 |
| PSAE 300 mg/kg | 35.0 ± 2.8 | 35.9 ± 2.8 | 38.0 ± 3.8 | 35.3 ± 2.8 |
| PSAE 2000 mg/kg | 30.8 ± 5.1 | 35.0 ± 6.3 | 34.7 ± 6.3 | 40.2 ± 7.5 |
| Food consumption (g) | ||||
| Control | 19.5 ± 0.7 | 21.9 ± 0.8 | 23.0 ± 0.8 | 22.6 ± 1.3 |
| PSAE 50 mg/kg | 18.8 ± 1.0 | 21.3 ± 1.2 | 21.4 ± 1.0 | 21.1 ± 0.6 |
| PSAE 300 mg/kg | 22.6 ± 1.5 | 22.7 ± 1.3 | 22.9 ± 1.0 | 21.1 ± 1.7 |
| PSAE 2000 mg/kg | 16.2 ± 0.7 | 17.1 ± 1.2 | 17.1 ± 1.2 | 19.6 ± 1.3 |
|
| ||||
| Female | ||||
| Water consumption (mL) | ||||
| Control | 28.3 ± 3.2 | 29.7 ± 2.3 | 32.7 ± 1.8 | 30.3 ± 1.3 |
| PSAE 50 mg/kg | 31.1 ± 3.8 | 30.5 ± 2.3 | 33.2 ± 1.8 | 33.3 ± 0.9 |
| PSAE 300 mg/kg | 37.0 ± 3.0 | 33.8 ± 3.0 | 38.7 ± 1.9 | 35.1 ± 0.9 |
| PSAE 2000 mg/kg | 29.2 ± 2.8 | 29.5 ± 2.8 | 28.9 ± 2.2 | 29.7 ± 2.0 |
| Food consumption (g) | ||||
| Control | 14.0 ± 0.7 | 16.0 ± 0.4 | 16.1 ± 0.5 | 15.5 ± 0.6 |
| PSAE 50 mg/kg | 12.3 ± 0.4 | 14.1 ± 0.4 | 13.6 ± 0.9 | 13.9 ± 0.3 |
| PSAE 300 mg/kg | 15.4 ± 0.7 | 17.1 ± 0.4 | 17.1 ± 1.5 | 18.0 ± 1.0 |
| PSAE 2000 mg/kg | 12.6 ± 0.6 | 15.7 ± 1.8 | 15.8 ± 0.9 | 15.7 ± 1.4 |
Data were expressed as mean ± SEM. *P value < 0.05 is significant compared to control group; # P value < 0.05 is significant compared to baseline value; P value < 0.05 is significant compared to other groups.
Table showing changes in the relative organ weight of rats throughout the experimental period.
| Relative weight (%) | Control |
| ||
|---|---|---|---|---|
| (normal saline) | 50 mg/kg | 300 mg/kg | 2000 mg/kg | |
| Male | ||||
| Liver | 3.63 ± 0.13 | 3.60 ± .0.07 | 3.51 ± 0.12 | 3.61 ± 0.13 |
| Left kidney | 0.35 ± 0.01 | 0.36 ± 0.02 | 0.33 ± 0.01 | 0.34 ± 0.01 |
| Heart | 0.39 ± 0.02 | 0.36 ± 0.02 | 0.36 ± 0.01 | 0.32 ± 0.01 |
| Left lung | 0.25 ± 0.01 | 0.25 ± 0.01 | 0.23 ± 0.01 | 0.26 ± 0.01 |
| Spleen | 0.19 ± 0.01 | 0.21 ± 0.01 | 0.18 ± 0.01 | 0.18 ± 0.00 |
| Left testis | 0.49 ± 0.02 | 0.51 ± 0.03 | 0.48 ± 0.02 | 0.53 ± 0.01 |
| Female | ||||
| Liver | 3.44 ± 0.07 | 3.42 ± 0.05 | 3.34 ± 0.14 | 3.64 ± 0.13 |
| Left kidney | 0.34 ± 0.01 | 0.34 ± 0.02 | 0.35 ± 0.01 | 0.34 ± 0.01 |
| Heart | 0.37 ± 0.02 | 0.35 ± 0.01 | 0.34 ± 0.01 | 0.37 ± 0.01 |
| Left lung | 0.30 ± 0.01 | 0.28 ± 0.01 | 0.29 ± 0.02 | 0.26 ± 0.01 |
| Spleen | 0.24 ± 0.02 | 0.25 ± 0.01 | 0.25 ± 0.01 | 0.23 ± 0.01 |
| Left ovary | 0.04 ± 0.00 | 0.03 ± 0.001 | 0.03 ± 0.001 | 0.03 ± 0.001 |
Data were expressed as mean ± SEM. *P value < 0.05 is significant compared to control group; # P value < 0.05 is significant compared to baseline value; P value < 0.05 is significant compared to other groups.
Table showing changes in the haematological profile of rats throughout the experimental period.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Control | 50 | 300 | 2000 | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Male | ||||||||
| RBC (106/ | 6.7 ± 0.4 | 7.2 ± 0.3 | 6.9 ± 0.1 | 7.4 ± 0.2 | 6.8 ± 0.3 | 7.6 ± 0.2 | 6.1 ± 0.2 | 7.0 ± 0.3 |
| HB (g/dL) | 13.1 ± 0.3 | 14.0 ± 0.5 | 14.2 ± 0.2 | 14.5 ± 0.4 | 13.4 ± 0.2 | 14.4 ± 0.2 | 12.5 ± 0.2 | 13.5 ± 0.6 |
| PCV | 42.8 ± 0.9 | 45.5 ± 1.9 | 45.3 ± 0.3 | 46.4 ± 1.6 | 44.5 ± 0.9 | 52.3 ± 5.4 | 40.0 ± 1.8 | 43.2 ± 2.0# |
| MCV (fL) | 67.7 ± 0.7 | 63.7 ± 0.6 | 65.7 ± 1.2 | 63.0 ± 1.0 | 66.0 ± 1.9 | 62.0 ± 1.1 | 66.7 ± 1.2 | 61.5 ± 0.6 |
| MCH (pg) | 20.5 ± 0.3 | 19.7 ± 0.3 | 20.7 ± 0.4 | 19.6 ± 0.4 | 20.0 ± 0.5 | 19.0 ± 0.3 | 20.5 ± 0.4 | 19.3 ± 0.2 |
| MCHC (g/dL) | 30.5 ± 0.2 | 30.7 ± 0.2 | 31.7 ± 0.2 | 31.2 ± 0.2 | 30.3 ± 0.4 | 30.5 ± 0.3 | 31.1 ± 0.6 | 31.3 ± 0.3 |
| PLT (×109/ | 1028 ± 53 | 998 ± 149 | 956 ± 153 | 1013 ± 116 | 1122 ± 82 | 966 ± 106 | 760 ± 46 | 723 ± 162 |
| WBC (×103/ | 15.7 ± 1.3 | 11.4 ± 1.8 | 16.0 ± 1.3 | 19.1 ± 3.7# | 18.3 ± 1.8 | 15.3 ± 2.4 | 14.0 ± 1.5 | 10.8 ± 2.3 |
| Female | ||||||||
| RBC (106/ | 6.8 ± .01 | 6.5 ± 0.2 | 6.7 ± 0.3 | 6.9 ± 0.2 | 7.2 ± 0.1 | 7.1 ± 0.2 | 6.6 ± 0.2 | 6.9 ± 0.1 |
| HB (g/dL) | 14.1 ± 0.2 | 12.9 ± 0.7 | 13.3 ± 0.4 | 13.8 ± 0.3 | 14.3 ± 0.3 | 13.8 ± 0.4 | 12.7 ± 0.4 | 13.4 ± 0.2 |
| PCV | 44.3 ± 0.6 | 40.4 ± 2.4 | 42.2 ± 1.8 | 43.5 ± 0.8 | 44.7 ± 0.7 | 42.2 ± 1.2 | 39.8 ± 1.0 | 41.7 ± 0.4 |
| MCV (fL) | 65.0 ± 0.5 | 61.4 ± 1.1 | 63.0 ± 1.0 | 62.8 ± 0.7 | 62.0 ± 1.3 | 59.8 ± 0.6 | 60.8 ± 1.2* | 59.8 ± 0.8 |
| MCH (pg) | 20.5 ± 0.2 | 19.8 ± 0.3 | 19.8 ± 0.4 | 20.2 ± 0.3 | 20.0 ± 0.6 | 19.6 ± 0.2 | 19.4 ± 0.5 | 19.3 ± 0.3 |
| MCHC (g/dL) | 31.7 ± 0.2 | 32.2 ± 0.2 | 31.5 ± 0.2 | 31.8 ± 0.2 | 32.0 ± 0.4 | 32.6 ± 0.4 | 32.0 ± 0.5 | 32.3 ± 0.2 |
| PLT (×109/ | 998 ± 68 | 671 ± 65* | 773 ± 128 | 947 ± 55 | 1086 ± 132 | 927 ± 60 | 858 ± 115 | 842 ± 116 |
| WBC (×103/ | 19.4 ± 2.3 | 11.8 ± 2.1 | 16.4 ± 1.1 | 10.5 ± 2.5 | 14.4 ± 2.1 | 13.6 ± 0.80 | 15.2 ± 3.0 | 11.7 ± 2.1 |
Data were expressed as mean ± SEM. *P value < 0.05 is significant compared to control group; # P value < 0.05 is significant compared to baseline value; P value < 0.05 is significant compared to other groups.
Table showing changes in the serum renal biochemical profile of rats throughout the experimental period.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Control | 50 | 300 | 2000 | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Male | ||||||||
| Urea (mmol/L) | 6.7 ± 0.5 | 7.6 ± 0.3 | 5.2 ± 0.1 | 7.2 ± 0.5# | 5.8 ± 0.2 | 7.8 ± 0.5# | 5.4 ± 0.5 | 6.2 ± 0.2 |
| Creatinine ( | 24.7 ± 4.9 | 26.7 ± 1.2 | 46.7 ± 0.8∗ | 28.2 ± 1.2# | 30.5 ± 6.0 | 32.0 ± 1.4 | 22.3 ± 1.1 | 33.2 ± 1.6 |
| Uric acid (mmol/L) | 0.05 ± 0 | 0.08 ± 0 | 0.06 ± 0.01 | 0.08 ± 0.01 | 0.07 ± 0.01 | 0.09 ± 0.02 | 0.03 ± 0 | 0.12 ± 0.03 |
| Sodium (mmol/L) | 140.8 ± 0.5 | 139.5 ± 0.7 | 139.8 ± 0.5 | 141.3 ± 0.3 | 140.2 ± 0.8 | 141.2 ± 0.8 | 140.7 ± 0.4 | 140.8 ± 0.4 |
| Potassium (mmol/L) | 4.5 ± 0.1 | 6.3 ± 0.3# | 5.2 ± 0.2 | 5.8 ± 0.3 | 5.2 ± 0.3 | 6.2 ± 0.2# | 4.2 ± 0.1 | 6.5 ± 0.2# |
| Chloride (mmol/L) | 98.8 ± 0.7 | 97.5 ± 0.2 | 101.3 ± 0.6* | 100.3 ± 0.4 | 99.7 ± 0.4 | 99.3 ± 0.9 | 99.5 ± 0.3 | 99.8 ± 0.6 |
| Female | ||||||||
| Urea (mmol/L) | 6.6 ± 0.2 | 8.0 ± 0.4 | 7.6 ± 0.2 | 8.2 ± 0.3 | 6.1 ± 0.3 | 6.8 ± 0.1 | 7.0 ± 0.4 | 7.7 ± 0.3 |
| Creatinine ( | 32.5 ± 3.7 | 28.5 ± 1.7 | 39.7 ± 1.4∗ | 30.2 ± 1.0# | 33.8 ± 1.4 | 31.8 ± 2.3 | 33.2 ± 2.0 | 31.3 ± 0.8 |
| Uric acid (mmol/L) | 0.10 ± 0.01 | 0.08 ± 0.01 | 0.09 ± 0.01 | 0.08 ± 0.01 | 0.07 ± 0.01 | 0.11 ± 0.02 | 0.04 ± 0.01 | 0.09 ± 0.01 |
| Sodium (mmol/L) | 141.2 ± 1.0 | 142.5 ± 0.7 | 140.2 ± 0.9 | 138.2 ± 0.5 | 138.0 ± 0.9 | 141.0 ± 0.9 | 139.5 ± 1.0 | 142.5 ± 0.5 |
| Potassium (mmol/L) | 4.9 ± 0.3 | 5.5 ± 0.1 | 4.8 ± 5.9 | 5.9 ± 0.2# | 4.7 ± 0.2 | 5.3 ± 0.1 | 4.2 ± 0.2 | 5.6 ± 0.3# |
| Chloride (mmol/L) | 102.2 ± 1.1 | 99.0 ± 1.3 | 101.0 ± 0.7 | 100.7 ± 0.8 | 99.4 ± 0.4 | 101.1 ± 1.0 | 98.5 ± 0.7 | 101.3 ± 0.9 |
Data were expressed as mean ± SEM. *P value < 0.05 is significant compared to control group; # P value < 0.05 is significant compared to baseline value; P value < 0.05 is significant compared to other groups.
Table showing changes in the serum liver biochemical profile of rats throughout the experimental period.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Control | 50 | 300 | 2000 | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Male | ||||||||
| Total protein (g/L) | 63 ± 1.1 | 64.3 ± 1.3 | 66.7 ± 0.9 | 63.3 ± 1.5# | 64.8 ± 1.2 | 66.2 ± 1.4 | 65.3 ± 2.3 | 65.3 ± 1.9 |
| Albumin (g/L) | 34.3 ± 0.4 | 35.3 ± 0.8 | 34.5 ± 0.4 | 36.7 ± 0.8 | 34.2 ± 0.6 | 35.2 ± 0.7 | 35.0 ± 0.6 | 35.2 ± 0.8 |
| Globulin (g/L) | 32.0 ± 1.3 | 29.0 ± 0.9 | 32.2 ± 1.2 | 26.5 ± 0.9 | 30.5 ± 0.7 | 31.0 ± 1.3 | 30.3 ± 2.1 | 32.0 ± 0.9 |
| Bilirubin ( | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 |
| ALP (iu/L) | 531 ± 62 | 372 ± 44 | 355 ± 21* | 438 ± 39 | 416 ± 31 | 332 ± 31 | 473 ± 17 | 338 ± 13 |
| AST (iu/L) | 131 ± 18 | 108 ± 7 | 132 ± 20 | 147 ± 28 | 111 ± 8 | 115 ± 9 | 105 ± 7 | 139 ± 19 |
| ALT (iu/L) | 60 ± 4 | 67 ± 3 | 61 ± 2 | 84 ± 11 | 56 ± 4 | 66 ± 2 | 63 ± 5 | 67 ± 4 |
| GGT (iu/L) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Female | ||||||||
| Total protein (g/L) | 74.3 ± 1.3 | 71.3 ± 1.0 | 76.2 ± 2.0 | 66.7 ± 2.1# | 70.7 ± 1.3 | 69.7 ± 1.2 | 71.7 ± 2.3 | 71.5 ± 2.0 |
| Albumin (g/L) | 38.51.0 | 36.0 ± 0.5 | 37.3 ± 1.1 | 36.2 ± 1.6 | 35.0 ± 0.6 | 35.2 ± 0.6 | 36.5 ± 2.0 | 38.5 ± 1.3 |
| Globulin (g/L) | 34.8 ± 1.0 | 35.3 ± 0.8 | 38.8 ± 2.2 | 30.5 ± 0.6 | 35.2 ± 0.4 | 34.7 ± 0.8 | 35.2 ± 1.0 | 33.0 ± 0.9 |
| Bilirubin ( | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 | 1 ± 0 |
| ALP (iu/L) | 307 ± 35 | 291.3 ± 19 | 301 ± 20 | 260 ± 23 | 270 ± 25 | 265 ± 22 | 367 ± 46 | 286 ± 16 |
| AST (iu/L) | 171 ± 33 | 149 ± 9 | 173 ± 27 | 135 ± 11 | 146 ± 9 | 115 ± 2 | 129 ± 11 | 116 ± 9 |
| ALT (iu/L) | 61 ± 6 | 57 ± 3 | 101 ± 19∗ | 56 ± 3 | 69 ± 8 | 58 ± 3 | 63 ± 4 | 76 ± 4 |
| GGT (iu/L) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Data were expressed as mean ± SEM. *P value < 0.05 is significant compared to control group; # P value < 0.05 is significant compared to baseline value; P value < 0.05 is significant compared to other groups.
Figure 2The histology of renal cells with H&E staining method of rats treated with 50 mg/kg, 300 mg/kg, and 2000 mg/kg of Piper sarmentosum aqueous extract and normal saline for 28 consecutive days at 25 and 200 times magnification. There were no significant changes in the structure of the kidney cells observed in the histological section of the kidney tissues of the treatment groups. G: glomerulus; BM: basement membrane; PCT: proximal convoluted tubule; DCT: distal convoluted tubule; C: cortex; M: medulla; BS: Bowman's space.
Figure 3The histology of liver cells with H&E staining method of rats treated with 50 mg/kg, 300 mg/kg, and 2000 mg/kg of Piper sarmentosum aqueous extract and normal saline for 28 consecutive days at 50 and 200 times magnification. There were no significant changes showing congestion or destruction of liver cells observed in the histological section of the liver tissues of the treatment groups compared to the control group. PT: portal triad; PV: portal vein; He: hepatocyte; S: sinusoid; A: hepatic artery; D: bile duct.